Topoisomerase IIα expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1527-1531

  Tina, Elisabet ^a,b   Prenkert, Malin ^b   Höglund, Martin ^c   Paul, Christer ^d,e   Tidefelt, Ulf ^a,b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

1 D arabinofuranosylcytosine; Acute myeloid leukaemia; Daunorubicin; Flow cytometry; Topoisomerase

Indexed keywords

CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL ISOLATION; CELL POPULATION; CELL SURVIVAL; CELL VIABILITY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL CYCLE; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; TIME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; CELL SURVIVAL; CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; TIME FACTORS;

EID: 70449353711     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000597     Document Type: Article

References (17)

1. Kimby E, Nygren P and Glimelius B: A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol 40: 231-252, 2001.
2. Chu MY and Fischer GA: A proposed mechanism of action of 1-beta-D-arabinofuranosyl-cytosine as an inhibitor of the growth of leukemic cells. Biochem Pharmacol 11: 423-430, 1962.
3. Kufe DW and Spriggs DR: Biochemical and cellular pharmacology of cytosine arabinoside. Semin Oncol 12: 34-48, 1985.
4. Kellner U, Sehested M, Jensen PB, Gieseler F and Rudolph P: Culprit and victim - DNA topoisomerase II. Lancet Oncol 3: 235-243, 2002.
5. Cline SD and Osheroff N: Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes. J Biol Chem 274: 29740-29743, 1999.
6. Heck MM, Hittelman WN and Earnshaw WC: Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086-1090, 1988.
7. Tanoguchi K, Sasano H, Yabuki N, Kikuchi A, Ito K, Sato S and Yajima A: Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase IIα in human epithelial ovarian carcinoma and germ cell tumor. Mod Pathol 11: 186-193, 1998.
8. Uggla B, Möllgård L, Ståhl E, Mossberg L-L, Karlsson MG, Paul C and Tidefelt U: Expression of topoisomerase IIα in the G0/G1 cell cycle phase of fresh leukemic cells. Leuk Res 25: 961-966, 2001.
9. Villman K, Ståhl E, Liljegren G, Tidefelt U and Karlsson MG: Topoisomerase IIα expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol 15: 486-491, 2002.
10. Galimberti S, Testi R, Guerrini F, Fazzi R and Petrini M: The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia. J Chemother 15: 374-379, 2003.
11. Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A, Cros E and Dumontet C: In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 117: 860-868, 2002.
12. McKenna SL, West RR, Whittaker JA, Padua RA and Holmes JA: Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia 8: 1498-1502, 1994.
13. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K and Burke PJ: Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83: 517-530, 1994.
14. Uggla B, Tina E, Nahi H, Paul C, Hoglund M, Sirsjo A and Tidefelt U: Topoisomerase IIα mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia. Int J Oncol 31: 153-160, 2007.
15. Sundman-Engberg B, Tidefelt U, Liliemark J and Paul C: Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs. in vivo. Cancer Chemother Pharmacol 25: 252-256, 1990.
16. Goswami PC, Roti Roti JL and Hunt CR: The cell cycle-coupled expression of topoisomerase IIalpha during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation. Mol Cell Biol 16: 1500-1508, 1996.
17. Goswami PC, Sheren J, Albee LD, Parsian A, Sim JE, Ridnour LA, Higashikubo R, Gius D, Hunt CR and Spitz DR: Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regulated by the 3′-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation. J Biol Chem 275: 38384-38392, 2000.